Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis further elucidated the mechanistic involvement of benzoxazinone derivatives in HCC therapy, identifying six key pathways: cancer‐associated signaling (23 targets), proteoglycans in cancer (16), ErbB signaling (9), PI3K‐Akt pathway (14), EGFR tyrosine kinase inhibitor (TKI) resistance (8), and VEGF signaling (7) (Figure S10). The gene discussed is AKT1; the disease is hepatocellular carcinoma.